CORPORATE ACCESS

WINTER SPRINGS, Fla., Oct. 08, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter. "The resolution of the warning...

WINTER SPRINGS, Fla., Aug. 27, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman and Chief Technology Officer and Chris Scott, Chief Financial Officer, will participate in...

Reports second quarter 2019 revenue of $9.2 millionReports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20Updates full year earnings guidance WINTER SPRINGS, Fla., July 30, 2019 -- iRadimed Corporation (NASDAQ: IRMD), a leader in the...

WINTER SPRINGS, Fla., July 29, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that its Board of Directors unanimously appointed Leslie McDonnell, to succeed Roger Susi as President and Chief Executive Officer. Mr. Susi will step down as President and CEO...

WINTER SPRINGS, Fla., July 16, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 second quarter financial results before the market opens on Tuesday, July 30th. iRadimed management will host a conference call the same...

Reports first quarter 2019 revenue of $8.4 millionReports first quarter 2019 GAAP diluted EPS of $0.15 and non-GAAP diluted EPS of $0.13 WINTER SPRINGS, Fla., April 30, 2019 -- iRadimed Corporation (NASDAQ: IRMD), a leader in the development of innovative magnetic...

WINTER SPRINGS, Fla., April 16, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 first quarter financial results before the market opens on Tuesday, April 30th. IRADIMED management will host a conference call the same...

WINTER SPRINGS, Fla., April 02, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received FDA 510(k) clearance for neonatal use of the pulse oximetry ("SpO2") and Capnography ("CO2") monitoring features of its 3880 Magnetic Resonance Imaging...

Reports fourth quarter 2018 revenue of $8.3 millionReports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.16Announces 2019 full year and first quarter financial guidance WINTER SPRINGS, Fla., Feb. 06, 2019 -- IRADIMED CORPORATION...

WINTER SPRINGS, Fla., Jan. 22, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2018 fourth quarter financial results before the market opens on Wednesday, February 6th. IRADIMED management will host a conference call the...